Protease-activated receptor-2 activation in gastric cancer cells promotes epidermal growth factor receptor trans-activation and proliferation.

Dysregulated epidermal growth factor receptor (EGFR) signaling is involved in gastric cancer (GC) cell growth. However, the mechanism that sustains EGFR signaling in GC remains unknown. Since protease-activated receptor-2 (PAR-2), a G protein-coupled receptor, has been shown to trans-activate EGFR in several cell types, we examined the role of PAR-2 in GC. We show here that in vitro activation of PAR-2 enhances the growth of two GC cell lines, AGS and MKN28. In both these cell lines, PAR-2 trans-activated EGFR and inhibition of EGFR tyrosine kinase activity by AG1478 or specific EGFR siRNA completely prevented PAR-2-driven proliferation. Antibody blockade of EGF-like ligands to EGFR did not modify EGFR signaling or cell growth induced by PAR-2 activation. In contrast, PAR-2 promoted Src activation and interaction of this kinase with EGFR. In support of this, inhibition of Src kinase activity by PP1 or siRNA blocked PAR-2-induced EGFR signaling cascade and cell growth. Finally, PAR-2 was detectable in both normal and GC specimens, but its expression was more pronounced in GC than controls and correlated with activated EGFR. These data show that PAR-2 is overexpressed in GC and suggest a role of PAR-2 in EGFR trans-activation and cell growth.

[1]  N. Vergnolle,et al.  CLINICAL RELEVANCE OF PROTEINASE ACTIVATED RECEPTORS (PARS) IN THE GUT , 2005, Gut.

[2]  M. Asaka,et al.  Relationship between Helicobacter pylori infection and the prevalence, site and histological type of gastric cancer , 2004, Alimentary pharmacology & therapeutics.

[3]  E. Hahn,et al.  Helicobacter pylori associated gastric pathology. , 1999, Journal of physiology and pharmacology : an official journal of the Polish Physiological Society.

[4]  Y. Miyagi,et al.  Stimulation of cellular growth and adhesion to fibronectin and vitronectin in culture and tumorigenicity in nude mice by overexpression of trypsinogen in human gastric cancer cells , 1998, Clinical & Experimental Metastasis.

[5]  H. Friess,et al.  Co‐expression of heparin‐binding EGF‐like growth factor and related peptides in human gastric carcinoma , 1996, International journal of cancer.

[6]  T. Sawada,et al.  A role for protease-activated receptor-2 in pancreatic cancer cell proliferation. , 2004, International journal of oncology.

[7]  Y. Miyagi,et al.  Production of trypsins by human gastric cancer cells correlates with their malignant phenotype. , 1998, European journal of cancer.

[8]  G. Cottrell,et al.  c-Cbl Mediates Ubiquitination, Degradation, and Down-regulation of Human Protease-activated Receptor 2* , 2005, Journal of Biological Chemistry.

[9]  F. Sarkar,et al.  Epidermal growth factor receptor-related protein: a potential therapeutic agent for colorectal cancer. , 2003, Gastroenterology.

[10]  M. D'Andrea,et al.  Differential expression of protease-activated receptors-1 and -2 in stromal fibroblasts of normal, benign, and malignant human tissues. , 2001, The American journal of pathology.

[11]  M. Nishibori,et al.  MAP kinase-mediated proliferation of DLD-1 carcinoma by the stimulation of protease-activated receptor 2. , 2003, Life sciences.

[12]  M. Laburthe,et al.  Initiation of human colon cancer cell proliferation by trypsin acting at protease-activated receptor-2 , 2001, British Journal of Cancer.

[13]  G. D. Hunter,et al.  Proteinase-activated receptors. , 2001, Pharmacological reviews.

[14]  W. MacNaughton Epithelial effects of proteinase-activated receptors in the gastrointestinal tract. , 2005, Memorias do Instituto Oswaldo Cruz.

[15]  M. Ogawa,et al.  Expression of proteinase-activated receptor-2 in human pancreatic cancer: a possible relation to cancer invasion and induction of fibrosis. , 2003, International journal of oncology.

[16]  L. Thiberville,et al.  Inhibition of tumor growth and metastatic spreading by overexpression of inter‐alpha‐trypsin inhibitor family chains , 2002, International journal of cancer.

[17]  M. Laburthe,et al.  Protease-activated Receptor 2 in Colon Cancer , 2004, Journal of Biological Chemistry.

[18]  H. Lane,et al.  ERBB receptors and cancer: the complexity of targeted inhibitors , 2005, Nature Reviews Cancer.

[19]  Michael Peyton,et al.  Aberrant epidermal growth factor receptor signaling and enhanced sensitivity to EGFR inhibitors in lung cancer. , 2005, Cancer research.

[20]  R. Lefkowitz,et al.  Gbetagamma subunits mediate Src-dependent phosphorylation of the epidermal growth factor receptor. A scaffold for G protein-coupled receptor-mediated Ras activation. , 1997, The Journal of biological chemistry.

[21]  N. Vergnolle,et al.  Review article: proteinase‐activated receptors — novel signals for gastrointestinal pathophysiology , 2000, Alimentary pharmacology & therapeutics.

[22]  A. Ullrich,et al.  Role of transactivation of the EGF receptor in signalling by G-protein-coupled receptors , 1996, Nature.

[23]  B. Strömbeck,et al.  Molecular cloning and functional expression of the gene encoding the human proteinase-activated receptor 2. , 1995, European journal of biochemistry.

[24]  M. Hollenberg,et al.  Glycosylation of human proteinase-activated receptor-2 (hPAR2): role in cell surface expression and signalling. , 2002, The Biochemical journal.

[25]  Robert J. Lefkowitz,et al.  Role of c-Src Tyrosine Kinase in G Protein-coupled Receptorand Gβγ Subunit-mediated Activation of Mitogen-activated Protein Kinases* , 1996, The Journal of Biological Chemistry.

[26]  A. Tarnawski,et al.  Prostaglandin E2 transactivates EGF receptor: A novel mechanism for promoting colon cancer growth and gastrointestinal hypertrophy , 2002, Nature Medicine.

[27]  S. M. Baker,et al.  Characterization of Protease-activated Receptor-2 Immunoreactivity in Normal Human Tissues , 1998, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[28]  N. Normanno,et al.  Immunohistochemical detection of cripto-1, amphiregulin and transforming growth-factor-alpha in human gastric carcinomas and intestinal metaplasias. , 1994, International journal of oncology.

[29]  S. Wiseman,et al.  Coexpression of the type 1 growth factor receptor family members HER‐1, HER‐2, and HER‐3 has a synergistic negative prognostic effect on breast carcinoma survival , 2005, Cancer.

[30]  S. Coughlin,et al.  PARticipation in inflammation. , 2003, The Journal of clinical investigation.

[31]  T. Okuda,et al.  Clinical significance of epidermal growth factor (EGF), EGF receptor, and c‐erbb‐2 in human gastric cancer , 1995, Cancer.

[32]  H. Kitagawa,et al.  Protease-activated receptor-2 expression and the role of trypsin in cell proliferation in human pancreatic cancers. , 2003, International journal of oncology.